Search research articles
Contact Us
Filters
Showing results (71-80 of 95) with videos related to
Page
of 10
Sort By:
Oncology Research
|
January 1, 1994
P-glycoprotein mediates profound resistance to bisantrene
X P Zhang, M K Ritke, J C Yalowich, et al.
Blood Cancer Discovery
|
September 8, 2022
Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
Lee M Greenberger, Larry A Saltzman, Lore M Gruenbaum, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 6, 2008
A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: design, synthesis, and biological activity
Terry V Hughes, Guozhang Xu, Steven K Wetter, et al.
Biochemistry
|
May 4, 2005
Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin
Maria Nunes, Joshua Kaplan, Joseph Wooters, et al.
Molecular Cancer Therapeutics
|
October 16, 2004
Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin
Frank Loganzo, Malathi Hari, Tami Annable, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 29, 2007
Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents
Ronghui Lin, Peter J Connolly, Yanhua Lu, et al.
Seminars in Hematology
|
April 26, 2023
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management
E Terpos, A R Branagan, R García-Sanz, et al.
Molecular Cancer Therapeutics
|
October 27, 2011
Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer
Yixian Zhang, Stephen Castaneda, Melissa Dumble, et al.
Journal of Medicinal Chemistry
|
August 10, 2001
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity
H R Tsou, N Mamuya, B D Johnson, et al.
Biochemical Pharmacology
|
March 23, 1999
Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)
C M Discafani, M L Carroll, M B Floyd, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 95) with videos related to
Sort By:
Page
of 10
Oncology Research
|
January 1, 1994
P-glycoprotein mediates profound resistance to bisantrene
X P Zhang, M K Ritke, J C Yalowich, et al.
Blood Cancer Discovery
|
September 8, 2022
Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
Lee M Greenberger, Larry A Saltzman, Lore M Gruenbaum, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 6, 2008
A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: design, synthesis, and biological activity
Terry V Hughes, Guozhang Xu, Steven K Wetter, et al.
Biochemistry
|
May 4, 2005
Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin
Maria Nunes, Joshua Kaplan, Joseph Wooters, et al.
Molecular Cancer Therapeutics
|
October 16, 2004
Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin
Frank Loganzo, Malathi Hari, Tami Annable, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 29, 2007
Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents
Ronghui Lin, Peter J Connolly, Yanhua Lu, et al.
Seminars in Hematology
|
April 26, 2023
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management
E Terpos, A R Branagan, R García-Sanz, et al.
Molecular Cancer Therapeutics
|
October 27, 2011
Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer
Yixian Zhang, Stephen Castaneda, Melissa Dumble, et al.
Journal of Medicinal Chemistry
|
August 10, 2001
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity
H R Tsou, N Mamuya, B D Johnson, et al.
Biochemical Pharmacology
|
March 23, 1999
Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)
C M Discafani, M L Carroll, M B Floyd, et al.
Page
of 10